On September 21, 2022 Helsinn Group ("Helsinn"), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, reported that two scientific abstracts have been accepted for oral presentation at the upcoming EORTC CLTG (European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumors Group) Annual Meeting 2022, taking place in Madrid, Spain from the 22-24 September (Press release, Helsinn, SEP 21, 2022, View Source [SID1234619715]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details on the presentations are below:
Presentations:
Title: A Post-hoc Analysis of Clinical Trial Data Shows that Prior Phototherapy Does Not Affect Response to Chlormethine Gel in Patients with Mycosis Fungoides
Authors: Chalid Assaf, Christiane Querfeld, Marta Scandurra, Marco Turini, Julia J. Scarisbrick
Date/Time: 23 September, 6:36pm CET
Presenter: Chalid Assaf, Prof. Dr. med., Chief Physician of the Clinic for Dermatology and Venerology, Helios Klinikum Krefeld, Germany
Title: Combination Therapy with Chlormethine Gel and Narrow-Band Ultraviolet B for Patients with Mycosis Fungoides: a Case Series
Authors: Laura Gleason, Daniel Joffe, Neda Nikbakht MD, PhD
Date/Time: 23 September, 5:12pm CET
Presenter: Laura Gleason, MD, Thomas Jefferson University, Department of Dermatology and Cutaneous Biology, Philadelphia, US
During the conference Helsinn will also be sponsoring a satellite symposium which will focus on chlormethine’s mechanism of action. The symposium, entitled "A multi-level analysis of chlormethine: from skin cells to clinical cases", will involve experts in the field of mycosis fungoides, including Prof. Pablo Ortiz-Romero, Head of Dermatology at University Hospital 12 de Octubre in Madrid, Spain and Prof. Emmanuella Guenova, Dermatologist at the Lausanne University Hospital, Switzerland and one of the leading researchers of the chlormethine molecule.
Satellite symposium
Title: A multi-level analysis of chlormethine: from skin cells to clinical cases
Date/Time: Thursday 22 September/1:30-2:30pm CET
Presenters: Emmanuella Guenova and Pablo Ortiz-Romero
Dr. Silvia Sebastiani, Group Head of Medical Affairs, commented: "It’s fantastic to see the growing body of data emerging from in vitro, clinical and case studies of LEDAGA/VALCHLOR for the treatment of this rare skin lymphoma. We’re pleased to be taking part in EORTC CLTG, sharing our own findings, as well as hearing the latest insights from across the cutaneous lymphoma research landscape. We remain committed to support the global MF-CTCL patient population."
Prof. Pablo Ortiz-Romero Head of Dermatology at University Hospital 12 de Octubre, added: "There is currently no cure for patients living with MF-CTCL and treatment goals are mainly aimed at reducing the abnormal appearance of the skin and to control any itching or other symptoms. I am delighted to Chair the Helsinn satellite symposium where emerging new data regarding chlormethine’s mode of action will be discussed, as well as interesting insights from Professor Guenova‘s clinical experience. The latest research further delineates the mechanism of LEDAGA/VALCHLOR in the treatment of this rare skin cancer."
Chlormethine gel 0.016%, also known as mechlorethamine gel, is approved in multiple countries, including the EU and US, and is marketed under the trade names LEDAGA and VALCHLOR. The authorized use for each country varies based on the design of the registrational trial and the individual health authority requirements. For more details, please refer to the approved product information for each respective jurisdiction.